BioSpace

In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We discuss why Australia has become a magnet for early clinical development, and whether its speed, regulatory clarity and tax incentives are pushing it toward a more integrated biotech role. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Jerome Barley , Commercial Director, Avion Medical Ryan Klein , Vice President, Business Development, US and APAC, Resolian Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Merck stole the show at the European Society for Medical Oncology (ESMO) annual conference, with new data on its Moderna-partnered personalized cancer vaccine leaking prior to the presentation and antibody-drug conjugate sac-TMT making a splash in endometrial cancer; Bristol Myers Squibb revealed the death of a patient with multiple sclerosis in an early-stage trial of zola-cel; and pharma is on track to easily surpass last year’s deal count.

In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Bruce Culleton , CEO, ProKidney Demetri Maxim , CEO, Nephrogen Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run; and the ESMO conference gets underway in Madrid this week, with much-anticipated data from Merck and Summit Therapeutics.

BioSpace Vice President Chantal Dresner and Angela Gabriel, content manager, life sciences careers, cover what happened in the biopharma job market during the third quarter. They discuss encouraging signs for those looking for their next opportunity, such as improved job postings live on the BioSpace website and a dramatic drop in layoffs. Other topics include signs of industry health, news about job opportunities and advice for the Q4 job hunt.

In this episode of Denatured, sponsored by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we discuss how biopharma has long invested in more data and visibility, yet many programs still face delays and scale-up surprises. The real challenge isn’t information overload—it’s building confidence in the decisions that steer scientific progress from development through commercialization. This episode is presented in partnership with Cytiva . Host Jennifer Smith-Parker , Director of Insights, BioSpace Guest Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions, Cytiva Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations

Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with certain mutations; and Caribou Biosciences may be on its way out.

In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t — and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Jennifer McMahon , Partner, Seroba Joey Mason , Venture Partner, Claret Capital Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?

In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster. Host ⁠Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Max Bronstein , CEO, Aviva Strategies Teresa Barnes , Chief Executive Warrior, PF Warriors Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimmune disease.

In this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice president and head of Global Clinical Development. We examine radioligand therapy’s accelerating momentum and how its diagnostic and therapeutic reach could potentially reshape care for more than 14 million patients worldwide. We also discuss Curium's push to expand US capacity and scale up at pace, and critically what success could mean for patients with cancer in the years ahead. This episode is presented in partnership with Curium . Host Jennifer Smith-Parker , Director of Insights, BioSpace Guests Mike Patterson , CEO North America, Curium Sabine Brookman-May , VP and Head of Global Clinical Development, Curium Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Novo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconvinced it will be enough to turn things around; Viking Therapeutics and Roche report positive results for their weight loss assets; Ultragenyx snags FDA approval for its Sanfilippo syndrome gene therapy; IPOs keep on coming.

In this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye Institute, and Wesley Jackson, chief science officer at Valitor. We talk about the eye condition call wet age-related macular degeneration (AMD), the limits of anti‑VEGF therapy and the push for true durability to change a patient’s life. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Philip Jacob Rosenfeld , Professor of Ophthalmology, University of Miami Health System, Bascom Palmer Eye Institute Wesley Jackson , Chief Science Officer, Valitor Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing the Prescription Drug User Fee Act the day after launching its TrialBlazer initiative. Meanwhile, Definium Therapeutics notched another late-stage trial win for its LSD drug, and Novartis continues to reel from the company’s triple asset stumble.

In this episode of Denatured, sponsored by SK Pharmteco, Jennifer Smith-Parker speaks to Arvind Singh, vice president and global head of supply chain. In this episode, we discuss how CDMOs are revamping supply‑chain strategy for a new generation of intricate modalities. Topics addressed include moving from smarter raw‑material sourcing and precision cold‑chain logistics to navigating geopolitical and regulatory uncertainty and deploying AI to building sustainable, scalable capabilities from clinical through commercial. This episode is presented in partnership with SK Pharmteco . Host Jennifer Smith-Parker , Director of Insights, BioSpace Guest Arvind Singh , VP & Global Head of Supply Chain Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx’s big bet in Angelman syndrome failed to yield benefit in Phase 3 but Ionis’ Pharmaceuticals nabbed the first targeted approval for Alexander disease; and on the business side, biopharma investment is back in a big way.

In this episode of Denatured, you’ll listen to Christina Takke, managing partner at V-Bio Ventures and Mariette van der Velden-Roesink, founding partner at Curie Capital. We examine why Benelux delivers world‑class science yet remains an investment patchwork, and what it will take to knit the region into a truly unified biotech investment corridor. Host ⁠Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Christina Takke , Managing Partner, V-Bio Ventures Mariette van der Velden-Roesink , Founding Partner, Curie Capital Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbreaking pancreatic cancer drug; BioNTech suspends a mid-stage trial of its mRNA cancer immunotherapy after a futility analysis; and nine mid-sized biopharma companies join their big pharma peers in President Donald Trump’s Most Favored Nation drug pricing scheme.

In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From trial endpoints and placebo effects to neuroplasticity modulation, we explore what it will take to build a sustainable path to the first approved therapy. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Hilary Rosselot , Executive Director, National Fragile X Foundation Jordi Fàbrega , Co-Founder & CEO, CONNECTA Therapeutics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.